Arbutus Biopharma Corp

ABUS · Moat type: REGULIERUNG

MoatScore

1/10

Fair Value

n/a

Margin of Safety

n/a

Rating

MEIDEN

Arbutus Biopharma is a clinical-stage biotechnology company that generates licensing revenues from patent-protected RNA interference and lipid nanoparticle technology as well as develops its own antiviral therapeutics against Hepatitis B.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.